From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy

Giampieri, Riccardo; Ziranu, Pina; Daniele, Bruno; Zizzi, Antonio; Ferrari, Daris; Lonardi, Sara; Zaniboni, Alberto; Cavanna, Luigi; Rosati, Gerardo; Casagrande, Mariaelena; Pella, Nicoletta; Demurtas, Laura; Zampino, Maria Giulia; Sozzi, Pietro; Pusceddu, Valeria; Germano, Domenico; Lai, Eleonora; Zagonel, Vittorina; Codecà, Carla; Libertini, Michela; Puzzoni, Marco; Labianca, Roberto; Cascinu, Stefano; Scartozzi, Mario

doi:10.3390/cancers12051330

In the last decade, a series of analyses failed to identify predictive biomarkers of resistance/susceptibility for anti-angiogenic drugs in metastatic colorectal cancer (mCRC). We conducted an exploratory preplanned analysis of serum pro-angiogenic factors (SErum aNgiogenesis-cenTRAL) in 72 mCRC patients enrolled in the phase II CENTRAL (ColorEctalavastiNTRiAlLdh) trial, with the aim to identify potential predictive factors for sensitivity/resistance to first line folinic acid-fluorouracil-irinotecan regimen (FOLFIRI) plus bevacizumab.

Titolo:	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy
Autori:	GIAMPIERI, RICCARDO [Formal Analysis] Ziranu, Pina Daniele, Bruno ZIZZI, ANTONIO [Formal Analysis] Ferrari, Daris Lonardi, Sara Zaniboni, Alberto Cavanna, Luigi Rosati, Gerardo Casagrande, Mariaelena Pella, Nicoletta Demurtas, Laura Zampino, Maria Giulia Sozzi, Pietro Pusceddu, Valeria Germano, Domenico Lai, Eleonora Zagonel, Vittorina Codecà, Carla Libertini, Michela Puzzoni, Marco Labianca, Roberto Cascinu, Stefano [Supervision] Scartozzi, Mario [Conceptualization] (Corresponding) mostra contributor esterni nascondi contributor esterni
Data di pubblicazione:	2020
Rivista:	CANCERS
Abstract:	In the last decade, a series of analyses failed to identify predictive biomarkers of resistance/susceptibility for anti-angiogenic drugs in metastatic colorectal cancer (mCRC). We conducted an exploratory preplanned analysis of serum pro-angiogenic factors (SErum aNgiogenesis-cenTRAL) in 72 mCRC patients enrolled in the phase II CENTRAL (ColorEctalavastiNTRiAlLdh) trial, with the aim to identify potential predictive factors for sensitivity/resistance to first line folinic acid-fluorouracil-irinotecan regimen (FOLFIRI) plus bevacizumab.
Handle:	http://hdl.handle.net/11566/281416
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11566/281416

Citazioni

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: